Respiratory Disorders Clinical Trial
Official title:
A Two-part, Randomised, Placebo-controlled Study to Investigatethe Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single Doses of Inhaled GSK1995057 in Healthy Subjects
GSK1995057 is a fully human, single domain antibody directed against the TNFR1 receptor. The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of inhaled GSK1995057 in healthy subjects. The study will be in two parts. Part 1 is a single-dose escalating design of 5 sequential cohorts of healthy subjects. Part 2 is a single-dose, parallel group design comprising 2 groups of healthy subjects assessing the effect of GSK1995057 on lung inflammation following inhaled LPS challenge. Actual dose administered in Part 2 will be determined from emerging safety and PK data from Part 1 and Study TFR110951.
This study will be a randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of inhaled GSK1995057 in healthy subjects. The study consists of 2 parts with a total of 6 cohorts. Part 1 will be conducted singleblind and Part 2 will be conducted single-blind with restrictions (i.e. subject and investigator only). The GSK Study Team and site pharmacist will remain unblinded to treatment allocation. Cohorts 1, 2, 3 and 4 (in Part 1) will receive a single inhaled dose of GSK1995057 or placebo. Cohort 5 will receive a single inhaled dose of GSK1995057 and in addition will have a bronchoalveolar lavage (BAL) sampling procedure conducted approximately 30 minutes post GSK1995057 dose. Subjects in Cohort 6 (Part 2) will be randomised to receive a high dose of GSK1995057 or placebo followed by an inhaled LPS challenge and BAL sampling procedure. Subjects will be required to visit the clinic over the course of 28 days after their dosing period for a follow up. Further visits for immunogenicity sampling may be conducted at 56 and 84 days post-first dose for subjects who show changes indicating a positive ADA response after dosing. Doses levels stipulated within the protocol are target doses based on predictions using the PK/PD model described in Section 1.2.2 of the clinical protocol. Part 1 will commence first and following acceptable safety and tolerability data will allow initiation of Part 2. All cohorts will participate in a single study session only. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Withdrawn |
NCT00844935 -
Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT01395849 -
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
|
N/A | |
Completed |
NCT03557645 -
Ventilator Hyperinflation and Hemodynamics
|
N/A | |
Completed |
NCT03281876 -
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
|
Phase 2 | |
Completed |
NCT01395862 -
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
|
N/A | |
Completed |
NCT01476046 -
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00835003 -
Timing of Planned Caesarean Section and Morbidity of the Newborn
|
N/A | |
Completed |
NCT03443427 -
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
|
Phase 2 | |
Completed |
NCT01360398 -
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
|
N/A | |
Completed |
NCT03201211 -
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
|
Phase 1 | |
Completed |
NCT02075541 -
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.
|
Phase 2 | |
Completed |
NCT00455767 -
Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
|
Phase 2 | |
Withdrawn |
NCT01505556 -
Proprioceptive Postural Control and Diaphragm Paresis
|
||
Completed |
NCT01505582 -
Inspiratory Muscle Training and Low Back Pain
|
N/A | |
Completed |
NCT02322671 -
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01818024 -
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT02316379 -
Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration
|
Phase 1/Phase 2 | |
Completed |
NCT01516437 -
A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD
|
N/A | |
Recruiting |
NCT02272049 -
Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults
|
Phase 1/Phase 2 |